This text of Oregon § 459A.227 (Public awareness) is published on Counsel Stack Legal Research, covering Oregon primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.
(1)A program operator must promote, and provide public outreach and education about, the safe and secure collection of covered drugs under the drug take-back program through the use of a website and written materials provided at the time a covered drug is delivered to a covered entity, and through the use of any signage, advertising or other means of fostering public awareness. At a minimum, a program operator must:
(a)Promote the safe and secure storage of covered drugs by covered entities;
(b)Disseminate information on the inherent risks of improperly storing or disposing of opioids or opiates and other covered drugs;
(c)Discourage the disposal of covered drugs in the garbage or sewer system;
(d)Promote the disposal of covered drugs through the use of the drug take-back program;
Free access — add to your briefcase to read the full text and ask questions with AI
(1) A program operator must promote, and provide public outreach and education about, the safe and secure collection of covered drugs under the drug take-back program through the use of a website and written materials provided at the time a covered drug is delivered to a covered entity, and through the use of any signage, advertising or other means of fostering public awareness. At a minimum, a program operator must:
(a) Promote the safe and secure storage of covered drugs by covered entities;
(b) Disseminate information on the inherent risks of improperly storing or disposing of opioids or opiates and other covered drugs;
(c) Discourage the disposal of covered drugs in the garbage or sewer system;
(d) Promote the disposal of covered drugs through the use of the drug take-back program;
(e) Establish a toll-free telephone number and a website address that a covered entity may use to contact the program operator about the drug take-back program;
(f) Publicize information on the location of drop-off sites, collection processes and any collection events;
(g) Work with authorized collectors to develop a readily recognizable and consistent design for repositories to be used at drop-off sites and to develop clear, standardized instructions to covered entities on how to use those repositories; and
(h) Conduct a biennial survey of covered entities and of pharmacists and health care providers who interact with covered entities.
(2) For purposes of conducting a survey under subsection (1)(h) of this section:
(a) In a form and manner prescribed by the Department of Environmental Quality, a program operator must submit proposed survey questions to the department for preapproval.
(b) Surveys must:
(A) Measure public awareness of the drug take-back program;
(B) Assess the extent to which drop-off sites, mail-back service and collection events are convenient and easy to use; and
(C) Assess knowledge of and attitudes toward the risks posed by improperly storing covered drugs and improperly discarding or abandoning covered drugs.
(3) A program operator shall coordinate with other program operators under this section to ensure that covered entities can easily identify, understand and access the services provided by all drug take-back programs that are operational in this state. At a minimum, all of the drug take-back programs that are operational in this state must provide a single toll-free telephone number and a single website address that a covered entity may use to contact program operators about the drug take-back programs and to acquire information about the location of the drop-off sites and the collection processes of the drug take-back programs.
(4) Upon request by a covered entity, a retail drug outlet, hospital with an on-site pharmacy or health care clinic with an on-site pharmacy must provide a covered entity with written materials provided by a program operator for the purpose of promoting the safe and secure collection of covered drugs at the time that a covered drug is delivered to a covered entity.